Quick Links
Contact us
Submit a medical question on an Otsuka product.
To discuss a medical inquiry on an Otsuka product, please call 1-800-441-67631-800-441-6763.
To report an adverse event or a product quality complaint, please call 1-800-438-99271-800-438-9927.
Featured news
Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. today presented new results from the Phase 3b study (NCT06973577) evaluating centanafadine in adults with attention-deficit/hyperactivity disorder and comorbid anxiety disorders at Psych Congress 2026 in New Orleans.
Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy (IgAN)
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. announced new data from the Phase 3 VISIONARY trial demonstrating that VOYXACT® (sibeprenlimab-szsi) stabilizes estimated glomerular filtration rate (eGFR) returning kidney function decline to baseline physiologic rate over two years (24 months) in adults with primary IgA nephropathy (IgAN) at risk for disease progression.
Otsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT® (sibeprenlimab-szsi) in IgA Nephropathy (IgAN) at GlomCon Hawaii 2026
Otsuka Pharmaceutical Development & Commercialization, Inc., announces that new data from the Phase 3 VISIONARY study will be presented at the GlomCon Hawaii 2026 conference taking place August 3-7, 2026. Building on recently reported topline results, the oral presentation will highlight key, two-year (24-month) VISIONARY estimated glomerular filtration rate (eGFR) and safety data in adults with primary IgA nephropathy (IgAN) at risk for disease progression. These data support Otsuka's rolling submission of a supplemental Biologics License Application (sBLA) to the U.S. FDA for traditional approval of VOYXACT® (sibeprenlimab-szsi). A complete analysis of the VISIONARY two-year eGFR results will be presented at an upcoming scientific congress.